{"filing":{"accession_number":"0001437749-26-030244","cik":"0001563665","ticker":"HRGN","company_name":"Harvard Apparatus Regenerative Technology, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-11","primary_document":"hrgn20260911_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1563665/000143774926030244/hrgn20260911_8k.htm"},"events":[{"id":33204,"run_id":30525,"accession_number":"0001437749-26-030244","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"On September 11, 2026, the Company entered into Securities Purchase Agreements for a private placement of 2,703,727 shares of common stock at $1.05 per share for aggregate proceeds of $2,838,911, plus a note conversion by the CEO of 683,725 shares for $717,911 of debt cancellation. The unregistered sale to accredited investors under Section 4(a)(2) and Rule 506 is material to investors assessing ownership dilution and capital structure.","company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36582,"accession_number":"0001437749-26-030244","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Company entered into Securities Purchase Agreements on September 11, 2026, for a private placement of 2,703,727 shares of common stock at $1.05 per share for aggregate proceeds of $2,838,911. This is a classic dilutive equity issuance. The inclusion of a note conversion by the CEO (683,725 shares for $717,911 of debt cancellation) further underscores the capital-raising nature and dilutive impact to existing shareholders. Private placements of this scale are material to investors assessing ownership dilution and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T14:12:56.861242+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36583,"accession_number":"0001437749-26-030244","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of common stock to accredited investors under Section 4(a)(2) and Rule 506, which is a private placement. The filing references Item 1.01 for details of the \"Private Placement,\" confirming this is a dilutive equity issuance. Such transactions are material to investors as they affect ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T14:12:56.861242+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36582,"accession_number":"0001437749-26-030244","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Company entered into Securities Purchase Agreements on September 11, 2026, for a private placement of 2,703,727 shares of common stock at $1.05 per share for aggregate proceeds of $2,838,911. This is a classic dilutive equity issuance. The inclusion of a note conversion by the CEO (683,725 shares for $717,911 of debt cancellation) further underscores the capital-raising nature and dilutive impact to existing shareholders. Private placements of this scale are material to investors assessing ownership dilution and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T14:12:56.861242+00:00","company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","filing_date":"2026-09-14"},{"id":36583,"accession_number":"0001437749-26-030244","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered sale of common stock to accredited investors under Section 4(a)(2) and Rule 506, which is a private placement. The filing references Item 1.01 for details of the \"Private Placement,\" confirming this is a dilutive equity issuance. Such transactions are material to investors as they affect ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T14:12:56.861242+00:00","company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","filing_date":"2026-09-14"}]}